Non-Alcoholic Steatohepatitis (NASH) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Non-Alcoholic Steatohepatitis (NASH) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Alcoholic Steatohepatitis (NASH) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline landscape.

Non-alcoholic steatohepatitis (NASH) is liver inflammation caused by a buildup of fat in the liver. NASH can get worse and cause scarring of the liver, which leads to cirrhosis. Symptoms of NASH include fatigue, weight loss for no clear reason, general weakness and an ache in the upper right part of belly. Risk factors include obesity, type 2 diabetes, high cholesterol and high triglycerides and metabolic syndrome.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Non-Alcoholic Steatohepatitis (NASH) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Non-Alcoholic Steatohepatitis (NASH) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 9, 67, 81, 13, 209, 98 and 4 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 2, 8 and 2 molecules, respectively.

Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal).
• The pipeline guide reviews pipeline therapeutics for Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal)

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned
Companies Mentioned

180 Life Corp
180 Life Sciences Corp
89bio Inc
AbbVie Inc
ABIONYX Pharma SA
Abivax SA
Abliva AB
Ache Laboratorios Farmaceuticos SA
Acquist Theraputics Inc
AdAlta Ltd
Addpharma Inc
Afimmune Biopharma Ltd
Akebia Therapeutics Inc
Akero Therapeutics Inc
Albireo Pharma Inc
Aldeyra Therapeutics Inc
Algernon Pharmaceuticals Inc
Aligos Therapeutics Inc
Allysta Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc
Altavant Sciences Inc
Altay Therapeutics Inc
Alteogen Inc
Altimmune Inc
Amgen Inc
Amytrx Therapeutics Inc
Angion Biomedica Corp
Anteris Bio
Anyuan Pharmaceutical Technology (Shanghai) Co Ltd
AptaBio Therapeutics Inc
AptamiR Therapeutics Inc
Araim Pharmaceuticals Inc
Arcturus Therapeutics Holdings Inc
Aria Pharmaceuticals Inc
Arkay Therapeutics LLC
Arrowhead Pharmaceuticals Inc
Artiam Bio Inc
Ascletis Pharma Inc
Asdera LLC
Ashvattha Therapeutics LLC
AstraZeneca Plc
Auransa Inc
Autophagy Science Co Ltd
Avaliv Therapeutics Inc
Avolynt Inc
Axcella Health Inc
Bast Biotechnology LLC
Belite Bio Inc
BenevolentAI Ltd
BerGenBio ASA
Betagenon AB
Bioio LLC
Biotoxtech Co Ltd
Bird Rock Bio Inc
Bisichem Co Ltd
Blade Therapeutics Inc
BLR Bio LLC
Boehringer Ingelheim International GmbH
Boston Pharmaceuticals Inc
Brexogen Inc
Bridge Biotherapeutics Inc
Bristol-Myers Squibb Co
Buto Corp
Cadila Healthcare Ltd
Can-Fite BioPharma Ltd
Cargene Therapeutics Inc
Carmot Therapeutics Inc
CellCure
Centaurus Therapeutics Inc
Chaser Therapeutics Inc
ChemoCentryx Inc
Chemomab Therapeutics Ltd
Chengdu Fanxi Biopharma Co Ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
China NT Pharma Group Co Ltd
Circadian Therapeutics
Cirius Therapeutics Inc
CK Regeon Inc
CohBar Inc
Continuum Biosciences Inc
Corbus Pharmaceuticals Inc
Corvidane
CSPC Pharmaceutical Group Ltd
Curacle Co Ltd
Curadim Pharma Co Ltd
Curome Bioscience Co Ltd
Cyrus Therapeutics Inc
Cytodyn Inc
D&D Pharmatech Co Ltd
Dr. Falk Pharma GmbH
DURECT Corp
Eccogene (Shanghai) Co Ltd
Elgia Therapeutics Inc
Eli Lilly and Co
Enanta Pharmaceuticals Inc
EncuraGen Co Ltd
Engitix Ltd
Ennovabio
Enspire Bio Inc
Enveda Biosciences Inc
Enyo Pharma SA
Enzychem Lifesciences Corp
Epigen Biosciences Inc
Epitracker Inc
Esperion Therapeutics Inc
Eternygen GmbH
F. Hoffmann-La Roche Ltd
f5 Therapeutics Inc
Fochon Pharmaceutical Ltd
Forma Therapeutics Inc
Future Medicine Co Ltd
Galectin Therapeutics Inc
Galecto Inc
Galmed Pharmaceuticals Ltd
GAT Therapeutics SL
Genentech USA Inc
General Regeneratives Shanghai Ltd
Genfit SA
GenKyoTex SA
GI Innovation Co Ltd
Gila Therapeutics Inc
Gilead Sciences Inc
Gmax Biopharm LLC
Guangdong East Sunshine Pharmaceutical Co Ltd
Guangdong Zhongsheng Pharmaceutical Co Ltd
Guangzhou BeBetter Medicine Technology Co Ltd
Hanmi Pharmaceuticals Co Ltd
HEC Pharma Co Ltd
HemoShear Therapeutics LLC
Hepagene Therapeutics Shanghai Inc
Hepanova Inc
HepaRegeniX GmbH
Hepatx Corp
Hepion Pharmaceuticals Inc
HighTide Therapeutics Inc
Hinova Pharmaceuticals Co Ltd
HK inno.N Corp
HotSpot Therapeutics Inc
Ildong Pharmaceutical Co Ltd
Imago Pharmaceuticals Inc
ImmuneMed Inc
Immupharma Plc
Immuron Ltd
Inipharm Inc
Inmune Bio Inc
Innovimmune Biotherapeutics Inc
Inorbit Therapeutics AB
Intarcia Therapeutics Inc
Integral Molecular Inc
Intercept Pharmaceuticals Inc
INVENT Pharmaceuticals Inc
InventisBio Inc
Inventiva SA
Inversago Pharma Inc
Ionis Pharmaceuticals Inc
J2H Biotech
JD Bioscience Inc
Jiangsu Atom Bioscience and Pharmaceutical Co Ltd
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Jiangsu Sinopep Allsino Biopharmaceutical Co Ltd
Johnson & Johnson
Kine Sciences
Kinomedica Pty Ltd
KoBioLabs Inc
Korea United Pharm Inc
Kowa Co Ltd
Krisani Bio Sciences Pvt Ltd
Kyorin Pharmaceutical Co Ltd
Laekna Therapeutics Shanghai Co Ltd
Landos Biopharma Inc
LegoChem Biosciences Inc
LG Chem Ltd
Life Biosciences LLC
LifeMax Laboratories Inc
Liminal BioSciences Inc
Lipidio Pharmaceuticals Inc
Lipocine Inc
LISCure Biosciences Co Ltd
Macrophage Pharma Ltd
Macrophage Therapeutics Inc
Madrigal Pharmaceuticals Inc
Marvel Biotechnology Inc
Max Biopharma Inc
MD Healthcare Inc
MedPacto Inc
Melior Pharmaceuticals I Inc
Merck & Co Inc
Metabolic Solutions Development Company LLC
Metabolys SAS
Metacrine Inc
MetiMedi Pharmaceuticals Co Ltd
Micelle BioPharma Inc
Mikrobiomik Healthcare Company SL
Mina Therapeutics Ltd
Mitotech SA
Mitotherapeutix LLC
Mitsubishi Tanabe Pharma Corp
Mperia Therapeutics Inc
Muen (Guangzhou) Biological Technology Co Ltd
Nanjing Aimeifei Biomedical Technology Co Ltd
Nanjing Sanhome Pharmaceutical Co Ltd
Nano Intelligent Biomedical Engineering Corp
NeuroBo Pharmaceuticals Inc
Nexel Co Ltd
Nextgen Bioscience
NGM Biopharmaceuticals Inc
Nippon Chemiphar Co Ltd
Nivarta Inc
NorthSea Therapeutics BV
Novartis AG
Novo Nordisk AS
NovoBiome SAS
NuSirt Biopharma Inc
Oasis Pharmaceuticals LLC
OliX Pharmaceuticals Inc
OncoArendi Therapeutics SA
Onegene Biotechnology Inc
Oramed Pharmaceuticals Inc
Osteoneurogen Inc
Oxitope Pharma BV
Palo BioFarma SL
Panolos Bioscience
Pattern Therapeutics
PegBio Co Ltd
Pfizer Inc
pH Pharma Co Ltd
Pharmaxis Ltd
Phenex Pharmaceuticals AG
Poxel SA
Promethera Biosciences SA
Proterris Inc
Protheragen Inc
PTC Therapeutics Inc
RadBio
Redx Pharma Plc
Regenasome Pty Ltd
Regulus Therapeutics Inc
Rejuvenation Technologies Inc
reMYND NV
Resalis Therapeutics Srl
Revive Therapeutics Ltd
Rhamnopharma Inc
Ridgeline Therapeutics LLC
Rivus Pharmaceuticals Inc
RosVivo Therapeutics Inc
Sagimet Biosciences
Saje Pharma LLC
Salix Pharmaceuticals Ltd
ScandiCure AB
Sciwind Biosciences Co Ltd
Scohia Pharma Inc
Seal Rock Therapeutics Inc
Senseion Inc
SFA Therapeutics LLC
Shaanxi Micot Technology Co Ltd
Shandong Danhong Pharmaceutical Co Ltd
Shanghai Anruite Biological Medicine Technology Co Ltd
Shaperon Inc
Shenzhen Chipscreen Biosciences Co Ltd
Shenzhen Tuwei Anchuang Technology Development Co Ltd
Shionogi & Co Ltd
Sihuan Pharmaceutical Holdings Group Ltd
Sinew Pharma Inc
Sino Biopharmaceutical Ltd
Sirnaomics Inc
SparkBioPharma Inc
Standigm Inc
SteroTherapeutics LLC
Sumitomo Dainippon Pharma Oncology, Inc
Suzhou Zelgen Biopharmaceutical Co Ltd
Sveikatal Inc
Synlogic Inc
T3D Therapeutics Inc
TaiwanJ Pharmaceuticals Co Ltd
Tasly Pharmaceutical Group Co Ltd
Terns Pharmaceuticals Inc
TES Pharma SRL
THELMA Therapeutics Co Ltd
Therasid Bioscience
Theratechnologies Inc
Thoth Science Inc
TiumBio Co Ltd
Tiziana Life Sciences Plc
TRACON Pharmaceuticals Inc
TransThera Sciences (Nanjing) Inc
TreeFrog Therapeutics SAS
TSD Life Sciences
UGISense AG
Uni-Bio Science Group Ltd
Unicyte AG
Valin Technologies Ltd
Vascular Biogenics Ltd
Vectus Biosystems Ltd
Venenum Biodesign LLC
Venn Therapeutics LLC
VGI Health Technology Ltd
Vidasym Inc
Viking Therapeutics Inc
Viscient Biosciences LLC
Visionary Pharmaceuticals Inc
Vivazome Therapeutics Pty Ltd
Vivoryon Therapeutics NV
Vivus LLC
vTv Therapeutics Inc
Wave Life Sciences Ltd
Xenexus Pharmaceuticals Pty Ltd
Xfibra Inc
Xi'an Xintong Pharmaceutical
Yuhan Corp
Zhangzhou Pien Tze Huang Pharmaceutical Co Ltd
Zhejiang Doer Biologics Corp
Zymedi